First, do no harm: Qt interval screening in methadone maintenance treatment

Journal of Addictive Diseases

Volumn 30, Issue 4, 2011, Pages 309-312

  Haigney, Mark C ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE;

ARTICLE; DRUG EFFECT; HUMAN; MEDICAL EXPERT; METHADONE TREATMENT; OPIATE ADDICTION; PRACTICE GUIDELINE; QT INTERVAL; SCREENING TEST; TORSADE DES POINTES;

HUMANS; LONG QT SYNDROME; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT SAFETY; TORSADES DE POINTES; UNITED STATES; UNITED STATES SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION;

EID: 84855780124     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550887.2011.610704     Document Type: Article

References (11)

1. Martin JA, Campbell A, Killip T, et al. QT interval screening in methadone maintenance treatment: report of a SAMHSA Expert Panel. J Addict Dis 2011; 30:283-306.
2. Krantz MJ, Martin J, Stimmel B, Mehta D, Haigney MC. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150:387-95.
3. Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009;104(6):993-9.
4. Chugh SS, Socoteanu C, Reinier K, et al. A community-based evaluation of sudden death associated with therapeutic levels of methadone.AmJ Med 2008; 121: 66-71.
5. Drew BJ, Ackerman MJ, Funk M, et al.; and the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology; Council on Cardiovascular Nursing; American College of Cardiology Foundation. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121:1047-60.
6. Soyka LF,Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. AmJ Cardiol 1990; 65(Suppl):74A-81A. (Pubitemid 20019030)
7. Brendorp B, Elming H, Jun L, et al., for the DIAMOND Study Group. QT interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001; 103:1422-27.
8. Pedersen HS, Elming H, Seibaek M, et al.; DIAMOND Study Group. Risk factors and predictors of Torsade de pointes ventricular tachycardia in patients with left ventricular systolic dysfunction receiving Dofetilide. Am J Cardiol 2007; 100:876-80. (Pubitemid 47268281)
9. Patel AM, Singh JP, Ruskin JN. Role of implantable cardioverter- defibrillators in patients with methadoneinduced long QT syndrome. Am J Cardiol 2008; 101:209-11.
10. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. JElectrocardiol 2007; 40:228-34.
11. Wedam EF, Bigelow G, Nuzzo P, et al. QT interval effects of methadone, levomethadyl acetate, and buprenorphine in a randomized trial. Arch InternMed2007; 167:2469-75.